Theorem Clinical Research & Gallus BioPharmaceuticals Announce Exclusive Partnership
Theorem Clinical Research has entered an exclusive partnership with Gallus BioPharmaceuticals in which Gallus will provide process development and clinical and commercial supply for mammalian cell-based biopharmaceutical products to Theorem’s customers. In return, Theorem will offer contract research services to Gallus’ customers to increase both companies’ global reach and accelerate their customers’ products through the clinic to market.
Gallus and Theorem have indicated their collaboration is aimed at addressing various time and cost issues in the current working relationship between sponsor companies and service providers by supporting the needs of their customers to outsource the research, development, and ultimate commercial production of products more cost effectively and to accelerate the path to market.
“Our intent is to make the process as seamless as possible,” said Gallus President and CEO Mark Bamforth.
Theorem is one of the industry’s leading full-service, global CROs providing core clinical research and development services. The company provides core CRO services for Phases I to IV, but with niche business units in the areas of clinical analytics, medical device, and pharmaceutics. Theorem Chief Executive Officer John Potthoff says that many of Theorem’s customers, especially those in Asia, need manufacturing assistance in the
Gallus is a world-class CMO, operating a commercially licensed manufacturing site in
Total Page Views: 938
